HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q3 2021 13F Holders as of 30 Sep 2021

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Number of holders
316
Total 13F shares, excl. options
130,048,093
Shares change
+1,166,757
Total reported value, excl. options
$5,289,784,296
Value change
+$44,615,821
Put/Call ratio
38.58%
Number of buys
171
Number of sells
-125
Price
$40.68

Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2021

359 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2021.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 316 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 130,048,093 shares .
Largest 10 shareholders include BlackRock Inc. (19,295,380 shares), VANGUARD GROUP INC (13,625,741 shares), Artisan Partners Limited Partnership (10,076,613 shares), STATE STREET CORP (5,575,317 shares), Invesco Ltd. (5,329,345 shares), JPMORGAN CHASE & CO (5,264,439 shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (4,996,708 shares), SNYDER CAPITAL MANAGEMENT L P (3,427,476 shares), MACQUARIE GROUP LTD (2,992,067 shares), and GEODE CAPITAL MANAGEMENT, LLC (2,458,973 shares).
This table shows the top 316 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.